AlzeCure Pharma AB (publ) (FN STO: ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company arranges a Capital Markets Day on May 17 at 10:00-11:30 CET with Professor Bengt Winblad as an invited guest speaker.
The aim of the day is to present the development of AlzeCure's Alzheimer's projects Alzstatin and NeuroRestore. Professor Bengt Winblad from Karolinska Institutet will also participate on this day, giving an update on the positive development in the Alzheimer field The presentations will be followed by a moderator-led Q&A session where there will be an opportunity to submit questions.
Presenters from AlzeCure are CEO Martin Jönsson, Dr. Pontus Forsell, Head of Discovery & Research and Dr. Johan Sandin, Chief Scientific Officer.
The Capital Markets Day takes place in collaboration with FinWire, requires no pre-registration and can be followed via https://www.finwire.tv/webcast/alzecure-pharma/presentation-17-maj/. The Capital Markets Day will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/sv/presentationer-och-intervjuer/.
Program:
10:00 Welcome address & agenda – Martin Jönsson, CEO, AlzeCure
10:02 AlzeCure Pharma: Overview, vision & update – Martin Jönsson, CEO, AlzeCure
10:10 Alzheimer’s disease, societal challenges & recent developments in the field – Professor Bengt Winblad, M.D., PhD, Karolinska Institute
10:25 Alzstatin: Background & evolution – Johan Sandin, PhD, CSO, AlzeCure
10:45 NeuroRestore: Background & data supporting disease modifying effects – Pontus Forsell, PhD, Head of Discovery & Research, AlzeCure
11:05 Panel discussion & QnA – Lead by Martin Westerberg, FinWire
11:25 Concluding remarks – Martin Jönsson, CEO, AlzeCure
